Needham & Company LLC Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $8.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 175.86% from the company’s current price.

Separately, Oppenheimer reiterated an “outperform” rating and set a $9.00 target price on shares of Trevi Therapeutics in a report on Thursday, March 21st.

Trevi Therapeutics Stock Down 0.7 %

Shares of NASDAQ TRVI opened at $2.90 on Wednesday. The stock has a market capitalization of $204.25 million, a price-to-earnings ratio of -10.07 and a beta of 0.91. Trevi Therapeutics has a 52 week low of $0.97 and a 52 week high of $4.00. The firm has a 50-day moving average price of $3.03 and a 200 day moving average price of $2.07.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. Equities research analysts expect that Trevi Therapeutics will post -0.39 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Trevi Therapeutics in the third quarter valued at $43,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at $208,000. Silverarc Capital Management LLC raised its position in shares of Trevi Therapeutics by 4.7% in the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock worth $2,022,000 after buying an additional 41,491 shares during the period. Opaleye Management Inc. boosted its holdings in Trevi Therapeutics by 48.6% in the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock valued at $3,397,000 after acquiring an additional 829,100 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. increased its stake in Trevi Therapeutics by 7.3% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after acquiring an additional 500,000 shares during the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.